ATLAS fair value
ATLAS has no fair value for this stock today.
Nyxoah stock price today, ATLAS forecast and fair value
Healthcare · Medical Devices · Euronext Brussels · Belgium
Prices as of Oct 26, 2026 · EUR
ATLAS has no fair value for this stock today.
46%
that it ends higher than today in 21 sessions
ATLAS's own quantitative analysis, all in one place.
Plans from €3.99 a month.
ATLAS's model gives Nyxoah a 46% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between €0.666 and €0.885; in 9 out of 10, between €0.517 and €1.14. Estimated annual volatility is 84%.
ATLAS does not publish a fair value for NYXH.BR right now, but it does show its odds of rising: close to a coin flip.
Over the last 52 weeks NYXH.BR has traded between €0.697 and €5.14. Today it is 84.7% below that high and 13% above its low.
Its beta is 1.00: it moves roughly in line with the market.
Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat obstructive sleep apnea. Its lead solution is the Genio system, a hypoglossal neurostimulations therapy for obstructive sleep apnea.
Want to see everything about Nyxoah?
Get started →Plans from €3.99 a month.
Other companies in the same line of business:
Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat obstructive sleep apnea. Its lead solution is the Genio system, a hypoglossal neurostimulations therapy for obstructive sleep apnea.
46%: close to a coin flip. In half of the simulated outcomes, NYXH.BR ends the month between €0.666 and €0.885.
Nyxoah's market capitalization is €113M. We do not show a P/E because it has no positive earnings to base one on.
ATLAS estimates annual volatility at 84%. In a typical month, half of the outcomes end between €0.666 and €0.885.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer
ATLAS Signals
The week in the market, three stocks on ATLAS’s radar and what comes next. Get it every Monday.
By subscribing you agree to receive ATLAS Signals by email every Monday. You can unsubscribe with one click at any time. Privacy